Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.

Oncogene - 5 Nov 2015

Komatsu N, Fujita Y, Matsuda M, Aoki K

Abstract excerpt

Cancer cells harboring oncogenic BRaf mutants, but not oncogenic KRas mutants, are sensitive to MEK inhibitors (MEKi). The mechanism underlying the intrinsic resistance to MEKi in KRas-mutant cells is under intensive investigation. Here, we pursued this mechanism by live imaging of extracellular signal-regulated kinases (ERK) and mammalian target of rapamycin complex 1 (mTORC1) activities in oncogenic KRas or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Signal-Regulated MAP Kinases
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Multiprotein Complexes

Share to Phosphatidylinositol 3-Kinases

Share to Telomerase

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 2 Protein

Source

Identifiers

PMID: 25703330
DOI: 10.1038/onc.2015.16

Genes

TSC1
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.PMID 25703330Read ↗

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.Semantic proximity Read ↗

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathwaySemantic proximity Read ↗

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.Semantic proximity Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

Reporter-based screening identifies RAS-RAF stabilizing mutations as drivers of resistance to broad-spectrum RAS inhibition in colorectal cancerSemantic proximity Read ↗

Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cellsSemantic proximity Read ↗

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cellsSemantic proximity Read ↗

Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.Semantic proximity Read ↗

Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.